RxDoctor Payments Data

Adam Kuhlman, DO

Neurology · Madison Heights, MINPI 1932547932

Payments from drug & device makers

$9,432in general payments, 2019–2025

Across 67 payments — averaging $140.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Lundbeck LLC$2K
  • MDD US Operations, LLC$2K
  • Acadia Pharmaceuticals Inc$1K
  • Boston Scientific$697
  • AbbVie$303
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$2,80030%
  • Speaking & faculty fees$1,80019%
  • Travel & lodging$1,48916%
  • Food & beverage$3,34335%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,432 in reported general payments places this provider in the 70th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$69,631
Medicare patients
276
Services billed
1,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate62$386,659
RytaryCarbidopa/Levodopa96$137,650
GocovriAmantadine Hcl30$86,141
Carbidopa-LevodopaCarbidopa/Levodopa949$58,811
OngentysOpicapone24$23,200
Carbidopa-Levodopa ErCarbidopa/Levodopa145$14,768
Rasagiline Mesylate32$9,234
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone25$7,461
AmantadineAmantadine Hcl69$6,505
Propranolol Hcl ErPropranolol Hcl69$5,721
Primidone94$5,258
Ropinirole ErRopinirole Hcl28$4,662
Entacapone19$4,576
Selegiline Hcl28$3,645
Ropinirole Hcl67$2,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,271$386,65962 claims
Amneal Pharmaceuticals LLCRytary$237$137,65096 claims
MDD US Operations, LLCGocovri$1,600$86,14130 claims
Neurocrine Biosciences, Inc.Ongentys$59$23,20024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 652 neurology providers in Michigan.

Other neurology in Madison Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →